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Abstract
Background: The association between systemic sclerosis and pulmonary arterial hypertension
(PAH) is well recognized. Vascular endothelial growth factor (VEGF) has been reported to play an
important role in pulmonary hypertension. The aim of the present study was to examine the
relationship between systolic pulmonary artery pressure, clinical and functional manifestations of
the disease and serum VEGF levels in systemic sclerosis.
Methods: Serum VEGF levels were measured in 40 patients with systemic sclerosis and 13 control
subjects. All patients underwent clinical examination, pulmonary function tests and
echocardiography.
Results: Serum VEGF levels were higher in systemic sclerosis patients with sPAP ≥ 35 mmHg than
in those with sPAP < 35 mmHg (352 (266, 462 pg/ml)) vs (240 (201, 275 pg/ml)) (p < 0.01), while
they did not differ between systemic sclerosis patients with sPAP < 35 mmHg and controls. Serum
VEGF levels correlated to systolic pulmonary artery pressure, to diffusing capacity for carbon
monoxide and to MRC dyspnea score. In multiple linear regression analysis, serum VEGF levels,
MRC dyspnea score, and DLCO were independent predictors of systolic pulmonary artery pressure.
Conclusion: Serum VEGF levels are increased in systemic sclerosis patients with sPAP ≥ 35
mmHg. The correlation between VEGF levels and systolic pulmonary artery pressure may suggest
a possible role of VEGF in the pathogenesis of PAH in systemic sclerosis.
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Systemic sclerosis (SSc) is a chronic connective tissue dis-
ease characterised by excessive collagen deposition in the
skin and the internal organs and also by immunologic
abnormalities and vascular injury [1]. Pulmonary compli-
cations are very common in patients with SSc [2]. The
most frequent and serious pulmonary complication of SSc
is pulmonary hypertension (PH) which can occur in the
absence or presence of interstitial lung disease [3]. Clini-
cally significant pulmonary arterial hypertension (PAH)
affects 15–20% of scleroderma patients and results in dys-
pnea, impaired exercise tolerance, and a high risk of death
[4,5]. The pathogenesis of SSc remains unclear and thera-
peutic interventions are currently limited to symptomatic
relief and treatment of complications.
Vascular endothelial growth factor (VEGF) is an endothe-
lial cell-specific mitogen and a potent angiogenic peptide
which is secreted by a variety of cell types [6]. VEGF has
been shown to be implicated in several physiological and
pathological processes that require proliferation of
endothelial cells[7]. Serum VEGF concentrations are ele-
vated in many collagen diseases including SSc [8]. VEGF
levels correlate with pulmonary function tests in several
lung disorders such as asthma[9,10], chronic obstructive
pulmonary disease (COPD)[10,11], and diffuse paren-
chymal lung diseases[10,12]. It has also been reported
that VEGF plays an important role in the development of
pulmonary hypertension[13,14] and is strongly expressed
in the normal pulmonary circulation and within the plexi-
form lesions of primary pulmonary hypertension[15].
The aim of this study was to determine serum VEGF levels
in patients with SSc and to evaluate whether those levels
differ between patients with and without PAH not second-
ary to interstitial lung involvement of the disease. Further-
more we evaluated the relationship between VEGF levels




Forty patients with SSc (33 female, mean age 56.75 ± 12.5
years) and 13 healthy age-matched non smokers control
subjects, with no history of lung disease and normal pul-
monary tests, were included in the study. The diagnosis of
SSc in all patients was based on the Preliminary Criteria
for the Classification of Systemic Sclerosis[16]. All
patients underwent high resolution computed tomogra-
phy (HRCT) of the chest and pulmonary function tests
(PFTs). In a separate visit all patients underwent an
echocardiography by one experienced cardiologist (E.Z.).
Patients with conditions that could affect serum VEGF lev-
els or sPAP were not included in the study. Therefore, we
excluded patients with a smoking history (current smok-
ers or ex smokers), patients with a history of coronary
artery disease as well as subjects with diffuse left ventricu-
lar (LV) systolic dysfunction (Ejection Fraction <55%) or
segmental abnormalities revealed by echocardiography.
Moreover, we excluded patients with mitral or aortic valve
disorder. Finally, we did not include patients in which a
satisfactory envelope of tricuspid regurgitation (TR) could
not be detected by Doppler even with the use of infusion
of agitated saline.
Patients who received any kind of medication for pulmo-
nary hypertension or had a known history of arterial
hypertension receiving antihypertensive drugs, except cal-
cium channel blockers used for Raynaud's symptoms were
not included in the study. We also excluded patients with
pattern consistent with interstitial lung disease (ILD) (i.e.
subpleural opacities, parenchymal bands, thickened inter-
lobular septae, an irregular pleural interface, honeycomb
lung) in high resolution computed tomography, as those
patients were prone to develop PH secondary to chronic
respiratory disease.
Two experienced rheumatologists (L.S. and A.Z.) took a
detailed clinical history and performed thorough physical
examination. Disease duration was defined as duration of
skin involvement. Abnormal chest sounds, finger ulcers,
and total skin score were recorded for all patients. Dysp-
nea was evaluated with the Medical Research Council
(MRC) dyspnea score[17] Blood samples were obtained
from all patients and controls in order to measure serum
VEGF levels. All examinations and tests in each patient
were performed within a week.
The study protocol was approved by the local ethics com-
mittee and all patients gave written informed consent.
Pulmonary Function Tests
Pulmonary function tests (PFTs) included measurement
of FEV1, FVC, FEV1/FVC ratio, total lung capacity (TLC),
residual volume, diffusing capacity for carbon monoxide
(DLCO) and diffusing capacity for carbon monoxide
adjusted for alveolar volume (DLCO/VA). TLC and RV were
measured by the single breath helium dilution method
with a commercially available system (Master Screen,
Erich Jaeger GmbH, Wuerzburg, Germany). DLCO was
assessed by means of the single breath method with the
patient in the sitting position. Lung function measure-
ments were expressed as percentages of predicted values.
Tests were performed according to the American Thoracic
Society guidelines[18] by the same technician in order to
ensure the consistency of the results. In all patients, arte-
rial blood samples were taken for the measurement of
PaO2 and PaCO2 using a commercially available bloodPage 2 of 8
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Dyspnea
Patients' dyspnea was assessed with the modified (5-
point) Medical Research Council (MRC) dyspnea score
that consists of five questions asked to patients to assess
their breath discomfort according to the limitations they
are experiencing secondary to shortness of breath. Scores
on the modified Medical Research Council (MMRC) dys-
pnea scale can range from 0 to 4, with a score of 0 indicat-
ing the absence of dyspnea and 4 indicating that the
patient is too breathless to leave the house or becomes
breathless when dressing or undressing [17].
High resolution computed tomography (HRCT)
The HRCT examination of the chest was performed within
a 1-week interval from the pulmonary function tests and
collection of blood samples. The CT scans were performed
using either a Somaton HiQ or a Somaton Plus scanner
(Siemens, Erlanger, Germany). Scans were performed
with 1–1.5 mm section thickness and a 1–2 s scanning
time during breath holding at end inspiration. Films were
read blindly by a radiologist with expertise in HRCT and
the presence of subpleural opacities, parenchymal bands,
thickened interlobular septae, irregular pleural interface
or honeycombing was recorded.
Echocardiography
All patients underwent transthoracic echocardiogram by a
single investigator (E.Z.) who was blinded to the results of
the biochemical analyses and pulmonary function tests.
M-mode, two-dimensional colour Doppler and Tissue
Doppler imaging (TDI) were performed using standard
methodology and commercially available equipment (GE
Medical Systems-Vivid 3, Milwaukee, WI, USA, with a
1.5–3.6 MHz transducer)
Tricuspid regurgitant flow (TR) was identified by colour
flow Doppler and the peak tricuspid regurgitant velocity
was measured by continuous wave Doppler and transtri-
cuspid gradient was assessed, based on the modified Ber-
noulli equation[19]. The highest velocity obtained from
multiple views was used. Agitated saline was used to
enhance suboptimal Doppler signals[20]. The diameter of
the inferior vena cava and its respiratory variation were
used to estimate right atrial pressure which was added to
the transtricuspid gradient in order to estimate sPAP.
The mitral flow pattern was analysed using the pulsed-
wave Doppler technique, with the sample volume located
between the tips of the mitral leaflets. TDI was analysed
with sample volume located at the lateral site and the iner-
ventricular septum of the mitral annulus in the four cham-
ber view from the apical window. All results were the
average of at least three different beats.
Mild or moderate TR was found in all patients allowing a
quite good Doppler envelope. Although right ventricular
(RV) function was not in exclusion criteria, all patients
had fairly good systolic function without RV dilation; yet,
the interventricular septum performed a normal move-
ment i.e. without bulging towards the left ventricle. All
patients were in sinus rhythm; heart rate was less than
100/min during echo measurements. sPAP over 35
mmHg was used as a cut-off value for the presence of pul-
monary hypertension [21,22].
Blood samples
Blood samples were collected from all patients and con-
trol subjects during routine clinical procedures. Blood
samples were centrifuged in 1500 g for 10 min at 4°C and
serum was collected and frozen in -70°C until measure-
ment. Serum VEGF levels were measured with a commer-
cially available enzyme immunosorbent assay kit
(Biosource Europe S.A.; Nivelles; Belgium) according to
the protocol of the manufacturer. The lower limit of detec-
tion for VEGF was <5 pg/ml.
Statistical analysis
Comparisons between patients and controls as well as
between patients with and without PAH were performed
using a Kruskal-Wallis test and are presented as the
median (25th to 75th percentile) as variables were not nor-
mally distributed. Data were analysed using Spearman's
correlation coefficient for variables that were not nor-
mally distributed and Pearson's correlation coefficient for
variables which were normally distributed. In the multi-
variate analysis, a multiple linear regression model was
created using systolic pulmonary artery pressure as the
dependent variable and age, gender, disease duration,
total skin score, MRC dyspnea scale and serum VEGF con-
centrations as independent variables. A p value of <0.05
was considered to be statistically significant. Analysis was
performed using the SPSS 12 statistical package (SPSS,
Chicago, IL).
Results
A flow chart of the study participants is shown in Figure 1.
Demographic characteristics of the evaluated subjects are
presented in Table 1. The median disease duration for the
group of our patients was 6 years (range 1–21 years).
Twenty four of our patients had disease duration ≤ 5 years.
Skin lesions were present in all patients. However, during
the time that the study was performed only nine patients
had finger ulcers. The median total skin score of our study
group was 17.5 (range 1–48). Systolic pressure in the pul-
monary artery ≥ 35 mmHg was found in 20 patients.Page 3 of 8
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Serum VEGF levels in patients with SSc were higher than
in controls (267 (228, 387) pg/ml vs. 192 (169, 228) pg/
ml, respectively; p < 0.01). Patients with SSc and sPAP ≥
35 mmHg had significantly higher serum VEGF levels
than those without with SPAP < 35 mmHg (352 (266–
462)pg/ml vs. 240 (201–275).pg/ml respectively; p <
0.01) (Figure 2). Patients with SSc and sPAP ≥ 35 mmHg
had higher serum VEGF levels than controls (352 (266–
462) pg/ml vs. 192 (169, 228) pg/ml, respectively; p <
0.01) (Figure 2). No significant difference was found
between patients with SSc with sPAP < 35 mmHg and con-
trols (p > 0.05).
Correlations of serum VEGF levels
There was a significant correlation between serum VEGF
levels and sPAP (r = 0.578, p = 0.001) in patients with SSc
(Figure 3). Serum VEGF levels also presented a significant
correlation with the MRC dyspnea score (r = 0.341, p =
0.031) (Figure 4). Finally, serum VEGF levels presented a
significant negative correlation to the diffusing capacity
for carbon monoxide (DLCO) (r = -0.471, p = 0.002) (Fig-
ure 5) There was no statistically significant correlation
between serum VEGF levels, and disease duration, blood
gases, FEV1, FVC, FEV1/FVC ratio or total skin score in the
group of our patients.
Correlations of sPAP with clinical and functional 
parameters
sPAP significant correlated to the patients dyspnea (meas-
ured by the MRC dyspnea scale) and to the diffusing
capacity for carbon monoxide (r = 0.662, p < 0.001 and r
= -0.722, p < 0.001 respectively). There was no statistically
significant correlation between serum sPAP levels, and
arterial blood gases, FEV1, FVC, or FEV1/FVC ratio in the
group of our patients.
Multivariate analysis for determinants of sPAP
In the multiple linear regression analysis, sPAP was used
as dependent variable whereas age, gender, disease dura-
tion, total skin score, MRC dyspnea score, DLCO and serum
VEGF concentrations were used as independent variables.
The only independent determinants of sPAP (R2 = 0.724)
were serum VEGF levels (p = 0.020, β = 0.295), DLCO (p =
0.003, β = -0.454) and MRC dyspnea score (p = 0.018, β =
0.344). (Table 2)
Discussion
In the present study we have shown that serum VEGF lev-
els were elevated in patients with SSc and sPAP ≥ 35
mmHg compared to patients with SSc and sPAP < 35
mmHg and healthy controls. In addition, serum VEGF
levels were positively correlated to the levels of sPAP and
the degree of dyspnea as expressed by the modified MRC
scale and were negatively correlated to the diffusing capac-
ity for carbon monoxide (DLCO). Finally, in the multivari-
Flow chart of the study participantsigure 1
Flow chart of the study participants.
Table 1: Demographic Characteristics and summary of pulmonary function tests of the study participants*
Variables Systemic Sclerosis Controls p value
sPAP < 35 mmHg sPAP ≥ 35 mmHg
Participants, No. 20 20 13
Female/Male 16/4 17/3 10/3
Age, ys 55.0 ± 14.0 58.4 ± 10.7 55.3 ± 13.4 0.379
FEV1 (%predicted) 83.9 ± 12.5 87.8 ± 18.6 99.6 ± 5.3 0.425
FVC (%predicted) 84.1 ± 14.3 86.6 ± 22.2 99.0 ± 3.2 0.570
FEV1/FVC 85.6 ± 9.4 85.5 ± 6.9 76.5 ± 2.9 0.882
DLCO (%predicted) 89.9 ± 13.4 60.0 ± 21.8 101.0 ± 4.0 <0.0001
DLCO/VA (%predicted) 88.6 ± 19.9 77.6 ± 16.3 102.3 ± 3.5 0.033
PO2 (mmHg) 81.8 ± 5.0 75.5 ± 12.3 94,8 ± 1.9 0.561
PCO2 (mmHg) 38.6 ± 3.5 37.7 ± 5.8 38.8 ± 1.2 0.942
* Values are given as the mean ± SD unless otherwise indicated. sPAP: systolic pressure in the pulmonary artery, FEV1: Forced Expiratory Volume 
in 1 sec, FVC: Forced expiratory Vital Capacity, DLCO: Diffusing Capacity of the lungs for Carbon Monoxide, VA: alveolar volume.Page 4 of 8
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a determinant of sPAP, suggesting a possible role for VEGF
in the pathogenesis of PAH in patients with SSc.
The pathogenesis of SSc involves interplay between oblit-
erative vasculopathy in multiple vascular beds, inflamma-
tion, autoimmunity and progressive fibrosis [1,2,23].
Vascular injury and activation are the earliest and possibly
primary events in the pathogenesis of SSc [2]. Among the
manifestations of SSc-associated vasculopathy, PH is the
most severe and life-threatening one. Angiogenic factors
are likely to be involved in the initiation of endothelial
cell dysfunction and the development of pulmonary
hypertension [24] VEGF and its receptors flt-1 and flk-1
are expressed in the plexiform lesions in the lungs of
patients with severe PH. In addition, overexpression of
VEGF produces structures that resemble plexiform lesions
[25]. It is well known that chronic hypoxia increases lung
tissue VEGF expression and that VEGF is likely a modula-
tor of chronic hypoxia-induced pulmonary vascular
remodelling [26]. It has also been reported that VEGF is
increased in rats with hypoxia and monocrotaline-
induced PH and vascular remodelling [26,27]. These find-
ings have led to the hypothesis that VEGF may contribute
to the pathogenesis of PH by stimulating dysregulated
angiogenesis [25,28].
Our data are in agreement to previous studies which have
reported that serum VEGF levels are higher in patients
with SSc compared to controls [29]. It is known that VEGF
levels are increased under hypoxic conditions such as
reduced blood flow and reduced partial oxygen pressure
levels [6,30]. It is also known that systemic sclerosis is
associated with reduced capillary density which leads to a
reduced blood flow and thus to tissue ischemia and to
clinical manifestations such as fingertip ulcers [29]. How-
Serum VEGF levels in patients with SSc and in healthy con-trolsFig re 2
Serum VEGF levels in patients with SSc and in 
healthy controls. Data are shown as box plots, with upper 
and lower quartiles shaded. All: all patients with SSc, sPAP < 
35 mmHg: patients with sPAP < 35 mmHg, sPAP ≥ 35 mmHg: 
patients with sPAP ≥ 35 mmHg. **:p < 0.01, ***:p < 0.001, ns: 
non significant.
Correlation between serum VEGF levels and systolic pulmo-nary artery pr ssure ( PAP, mmHg) in patient  with SScFigure 3
Correlation between serum VEGF levels and systolic 
pulmonary artery pressure (sPAP, mmHg) in 
patients with SSc.
Correlation between serum VEGF levels and MRC dyspnea sc e in patien s with SScFigure 4
Correlation between serum VEGF levels and MRC 
dyspnea score in patients with SSc.
Correlation between serum VEGF levels and DLCO (% pre-dicted) in pati nts with SScFigure 5
Correlation between serum VEGF levels and DLCO (% 
predicted) in patients with SSc.Page 5 of 8
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was found between serum VEGF levels and either the
severity of skin lesions, expressed as the total skin score, or
the presence of finger ulcers. A plausible explanation for
this finding could be the fact that tissue hypoxia described
in SSc is not limited to the skin but also involves several
internal organs [2,23], which may contribute to the over-
all elevation of VEGF levels in the serum of these patients.
On the other hand, our data suggest that serum VEGF lev-
els are higher in patients with SSc and sPAP ≥ 35 mmHg
and do not differ between patients with SSc and sPAP < 35
mmHg and controls. This fact leads to the hypothesis that
increased VEGF levels might be related to the presence of
elevated pressure in the pulmonary artery rather than to
the disease on its own. Our findings may support the
hypothesis that elevated serum VEGF levels might reflect
an increase in VEGF production at sites of vascular injury
due to tissue hypoxia[25,28] which enhances dysregu-
lated angiogenesis in the pulmonary vasculature leading
to the development of PAH. However, as it can be
observed, there is an overlap in the sVEGF levels between
patients with sPAP ≥ 35 mmHg and patients with sPAP <
35 mmHg. In this study we excluded patients with condi-
tions that could affect sVEGF levels and for that reason the
causes for this overlap are difficult to be determined. Fur-
ther studies are needed to determine whether patients
with low sPAP and high sVEGF will develop PAH in the
future.
In contrast to the suggestion that VEGF plays a significant
role in the pathogenesis of PH, a recent report indicated
that VEGF likely plays an important role in the mainte-
nance of normal pulmonary vascular structure [31]. This
report suggested that VEGF is important in attenuating the
development of PH possibly by protecting endothelial
cells from injury and apoptosis [31]. It has been proposed
that VEGF is a potential mediator of endothelial cell pro-
liferation and thus it may act as a protective mechanism
against pulmonary vascular injury and remodelling [13].
It has also been reported that inhibition of VEGF receptor
flk-1 in animal models caused pulmonary hypertension
characterized by thickening of the medial layer of pulmo-
nary arteries in normoxic conditions [32]. Additionally,
severely hypoxic rats which were treated with an flk-1
inhibitor, developed PH which was accompanied by a
marked increase in endothelial cell proliferation in the
pulmonary artery [32]. This probable protective role of
VEGF during the development of PH can also be sup-
ported by the fact that VEGF increases local eNOS expres-
sion and stimulates NO release from vascular
endothelium [33]. Therefore, an alternative interpretation
of the increased serum VEGF levels in patients with SSc
and sPAP ≥ 35 mmHg, could be that the elevation of sPAP
might by itself be the cause of the induction of VEGF syn-
thesis and release from the pulmonary vasculature, in an
attempt to blunt the development of vascular remodelling
in the pulmonary vessels[33].
Our data have also shown a significant correlation
between serum VEGF levels and dyspnea as expressed by
the MRC dyspnea score. In patients with SSc, dyspnea
occurs either due to the involvement of the lung paren-
chyma or due to the development of PH, both potentially
resulting in oxygen desaturation especially during exercise
[2]. As previously mentioned, under hypoxic conditions
VEGF expression normally increases. However, no corre-
lation was found between VEGF levels and the values of
the arterial blood gases in our patients. Furthermore, arte-
rial PO2 did not differ significantly between the two
groups of our patients. A plausible explanation for the
absence of a significant correlation could be the fact that
blood gases were collected and measured at rest, whereas
the greater degree of hypoxia occurs during exercise and
MRC dyspnea score expresses dyspnea in activity.
Finally we have found a significant correlation between
serum VEGF levels and DLCO. In patients with SSc an iso-
lated reduction of DLCOwith normal lung volumes is
indicative of PAH [34]. According to the fact that reduced
DLCO in PAH occurs due to vascular damage, the correla-
tion between serum VEGF levels and DLCO provides fur-
ther implications that VEGF might play a role in the
pathogenesis of PAH in SSc.
There are certain limitations in the present study. First, we
did not perform right heart catheterization to confirm
Table 2: Multivariate analysis for determinants of sPAP
Variable B* SE β† (95% CI for B) p
Age 0.015 0.137 0.011 (-0.267, -0.297) 0.915
Gender -4.258 4.343 -0.107 (-13.184, 4.669) 0.336
Disease duration -0.282 0.358 -0.093 (-1.019, 0.454) 0.438
MRC dyspnea score 4.996 1.987 0.344 (0.913, 9.080) 0.018
Total skin score -0.083 0.177 -0.053 (-0.446, 0.280) 0.643
DLCO -0.316 0.095 -0.454 (-0.511, -0.122) 0.003
Serum VEGF 0.027 0.011 0.295 (0.005, 0.050) 0.020
*Unstandardised coefficient; †standardised coefficient; SE: standard error, Adjusted R2 = 0.724Page 6 of 8
(page number not for citation purposes)
BMC Pulmonary Medicine 2009, 9:18 http://www.biomedcentral.com/1471-2466/9/18sPAP measurement assessed by echocardiography. How-
ever, Doppler echocardiography is a reliable and repro-
ducible means of non-invasive assessment of sPAP
[19,35] that has been employed to detect PH in patients
with connective tissue diseases [36]. In our study we
excluded patients with left ventricular (LV) systolic dys-
function or known cardiac disease which could increase
sPAP due to increased left ventricular filling pressures.
Although LV diastolic dysfunction could contribute to the
increase of sPAP due to postcapillary hypertension this
does not seem possible as diastolic function assessed from
transmitral Doppler flow and TDI did not differ between
SSc patients with sPAP ≥ 35 mmHg and those with sPAP
< 35 mmHg. This is in keeping with a large study by
Aguglia et al. who did not consider the existence of SSc by
itself, as an independent factor affecting LV diastolic func-
tion in SSc patients [37]. Furthermore, it is a fact that a
great number of our patients had elevated estimated levels
of sPAP in echocardiography. A possible explanation for
that might be that the study participants were recruited
from a scleroderma clinic in a tertiary hospital suggesting
that they were patients who had more severe disease.
Another limitation is that our analyses are based in single
measurements of sPAP and serum VEGF levels which may
not reflect this relationship in the course of the disease.
Therefore, further prospective studies are needed to inves-
tigate whether the worsening in sPAP is followed by
increases in serum VEGF levels.
Conclusion
In conclusion, in our study we have shown that serum
VEGF levels are elevated in patients with systemic sclerosis
and sPAP ≥ 35 mmHg compared to SSc patients and sPAP
< 35 mmHg and to healthy controls. Although the exact
role of VEGF in the pathogenesis of PH and vascular
remodelling remains controversial, our findings suggest
that serum VEGF levels may be used as a predictor of sPAP
in patients with SSc. Further studies are promptly needed
in order to evaluate the importance of determining serum
VEGF levels for the early detection, monitoring and prog-
nosis of PAH in patients with SSc.
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